Gastric cancer and trastuzumab: First biologic therapy in gastric cancer

Therapeutic Advances in Medical Oncology

Volumn 5, Issue 2, 2013, Pages 143-151

  Gunturu, Krishna S ^a   Woo, Yanghee ^b   Beaubier, Nike ^b   Remotti, Helen E ^b   Saif, M Wasif ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b Columbia University College of Physicians and Surgeons and the Herbert Irving Cancer Center ^*  (United States)

Author keywords

gastric cancer; trastuzumab

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; TRASTUZUMAB;

ANEMIA; BASOLATERAL MEMBRANE; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONTINUOUS INFUSION; CONTRACEPTION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EXPOSURE; DYSGEUSIA; ENDOSCOPIC MUCOSAL RESECTION; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GASTRECTOMY; GENE AMPLIFICATION; GENE MUTATION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; IMMUNOHISTOCHEMISTRY; JAPAN; LETHARGY; LOADING DRUG DOSE; LUNG HYPOPLASIA; LYMPH NODE DISSECTION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEWBORN DEATH; OLIGOHYDRAMNIOS; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE PERIOD; PREGNANCY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SKELETON MALFORMATION; SOLID TUMOR; STOMACH CANCER; STOMACH MUCOSA; STOMATITIS; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

EID: 84877913457     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834012469429     Document Type: Review

References (34)

1. Bang Y. Chung H. Xu J. Lordick F. Sawaki A. Lipatov O. Al-Sakaff N. et al. (2009) Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 27(215 Suppl.): abstract 4556.
2. Bang Y. Kim Y. Yang H. Chung H. Park Y. Lee K. et al. (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D 2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379: 315–321.
3. Bang Y. van Cutsem E. Feyereislova A. Chung H. Shen L. Sawaki A. et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687–697.
4. Bianco A. (2004) Targeting c-erbB2 and other receptors of the c-erbB family: rationale and clinical applications. J Chemother 16(Suppl. 4): 52–54.
5. Bozzetti C. Negri F. Lagrasta C. Crafa P. Bassano C. Tamagnini I. et al. (2011) Comparison of HER 2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 104: 1372–1376.
6. Browne B. O'Brien N. Duffy M. Crown J. O'Donovan N. (2009) HER-2 signaling and inhibition in breast cancer. Curr Cancer Drug Targets 9: 419–438.
7. Cunningham D. Allum W. Stenning S. Thompson J. van de Velde C. Nicolson M. et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11–20.
8. Cunningham D. Starling N. Rao S. Iveson T. Nicolson M. Coxon F. et al. (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36–46.
9. Dassen A. Lips D. Hoekstra C. Pruijt J. Bosscha K. (2009) FDG-PET has no definite role in preoperative imaging in gastric cancer. Eur J Surg Oncol 35: 449–455.
10. Dikken J. van Sandick J. Maurits Swellengrebel H. Lind P. Putter H. Jansen E. et al. (2011) Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer 11: 329.
11. Fitzgerald R. Caldas C. (2004) Clinical implications of E-cadherin associated hereditary diffuse gastric cancer. Gut 53: 775–778.
12. Franklin W. Veve R. Hirsch F. Helfrich B. Bunn P. Jr. (2002) Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 29(1 Suppl. 4): 3–14.
13. Galizia G. Lieto E. Orditura M. Castellano P. Mura A. Imperatore V. et al. (2007) Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 31: 1458–1468.
14. Herbst R. (2004) Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59(2 Suppl.): 21–26.
15. Hofmann M. Stoss O. Shi D. Buttner R. van de Vijver M. Kim W. et al. (2008) Assessment of a HER 2 scoring system for gastric cancer: results from a validation study. Histopathology 52: 797–805.
16. Klapper L. Waterman H. Sela M. Yarden Y. (2000) Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 60: 3384–3388.
17. Lee S. Lee J. Soung Y. Kim H. Park W. Kim S. et al. (2003) BRAF and KRAS mutations in stomach cancer. Oncogene 22: 6942–6945.
18. Lim J. Yun M. Kim M. Hyung W. Park M. Choi J. et al. (2006) CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. Radiographics 26: 143–156.
19. Macdonald J. Smalley S. Benedetti J. Hundahl S. Estes N. Stemmermann G. et al. (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725–730.
20. Mammano E. Belluco C. Sciro M. Mencarelli R. Agostini M. Michelotto M. et al. (2006) Epidermal growth factor receptor (EGFR): mutational and protein expression analysis in gastric cancer. Anticancer Res 26(5A): 3547–3550.
21. Ohtsu A. Shah M. van Cutsem E. Rha S. Sawaki A. Park S. et al. (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29: 3968–3976.
22. Pinto C. Di Fabio F. Siena S. Cascinu S. Rojas Llimpe F. Ceccarelli C. et al. (2007) Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18: 510–517.
23. Rice T. Blackstone E. Rusch V. (2010) 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol 17: 1721–1724.
24. Ruschoff J. Dietel M. Baretton G. Arbogast S. Walch A. Monges G. et al. (2010) HER 2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457: 299–307.
25. Siegel R. Ward E. Brawley O. Jemal A. (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212–236.
26. Song Y. Huang J. Wang J. (2010) [Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma]. Chin J Cancer 29: 76–81.
27. Songun I. Putter H. Kranenbarg E. Sasako M. van de Velde C. (2010) Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11: 439–449.
28. van Cutsem E. Moiseyenko V. Tjulandin S. Majlis A. Constenla M. Boni C. et al. (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V 325 Study Group. J Clin Oncol 24: 4991–4997.
29. Wainberg Z. Lin L. DiCarlo B. Dao K. Patel R. Park D. et al. (2011) Phase II trial of modified FOLFOX 6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Cancer 105: 760–765.
30. Wolff A. Hammond M. Schwartz J. Hagerty K. Allred D. Cote R. et al. (2007) American Society of Clinical Oncology / College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118–145.
31. Yakes F. Chinratanalab W. Ritter C. King W. Seelig S. Arteaga C. (2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62: 4132–4141.
32. Yamashita-Kashima Y. Iijima S. Yorozu K. Furugaki K. Kurasawa M. Ohta M. et al. (2011) Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res 17: 5060–5070.
33. Yano T. Doi T. Ohtsu A. Boku N. Hashizume K. Nakanishi M. et al. (2006) Comparison of HER 2 gene amplification assessed by fluorescence in situ hybridization and HER 2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 15: 65–71.
34. Yarden Y. Sliwkowski M. (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127–137.